$1.84
6.60% yesterday
Nasdaq, Aug 25, 10:05 pm CET
ISIN
US36269B1052
Symbol
GANX

Gain Therapeutics Inc Stock price

$1.84
+0.15 8.88% 1M
-0.08 4.17% 6M
-0.32 14.81% YTD
+0.49 36.30% 1Y
-1.68 47.73% 3Y
-9.16 83.27% 5Y
-9.16 83.27% 10Y
-9.16 83.27% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
-0.13 6.60%
ISIN
US36269B1052
Symbol
GANX
Industry

Key metrics

Basic
Market capitalization
$66.2m
Enterprise Value
$59.9m
Net debt
positive
Cash
$6.7m
Shares outstanding
30.8m
Valuation (TTM | estimate)
P/E
- | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
17.9
Financial Health
Equity Ratio
60.5%
Return on Equity
-278.1%
ROCE
-
ROIC
-
Debt/Equity
0.1
Financials (TTM | estimate)
Revenue
- | $0.0
EBITDA
- | -
EBIT
- | $-21.7m
Net Income
- | $-19.5m
Free Cash Flow
$-18.5m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
- | -
EBIT
- | -6.7%
Net Income
- | 4.4%
Free Cash Flow
2.9%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
-
FCF per Share
$-0.6
Short interest
0.7%
Employees
24
Rev per Employee
$0.0
Show more

Is Gain Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Gain Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Gain Therapeutics Inc forecast:

12x Buy
92%
1x Hold
8%

Analyst Opinions

13 Analysts have issued a Gain Therapeutics Inc forecast:

Buy
92%
Hold
8%

Financial data from Gain Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 9.70 9.70
10% 10%
-
- Research and Development Expense 11 11
8% 8%
-
-20 -20
9% 9%
-
- Depreciation and Amortization 0.08 0.08
0% 0%
-
EBIT (Operating Income) EBIT -20 -20
9% 9%
-
Net Profit -20 -20
8% 8%
-

In millions USD.

Don't miss a Thing! We will send you all news about Gain Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Gain Therapeutics Inc Stock News

Neutral
GlobeNewsWire
14 days ago
Reached full enrolment of Phase 1b study evaluating GT-02287 in Parkinson's Disease (PD) with or without GBA1 mutations during 2Q 2025, earlier than anticipated Analysis of functional changes and biomarker activity at 90 days will be available during 4Q 2025 In July 2025 following the close of 2Q 2025, Gain completed an underwritten public offering that resulted in approximately $7.1 million of...
Neutral
GlobeNewsWire
about one month ago
BETHESDA, Md., July 24, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next-generation of allosteric small molecule therapies, today announced that the Company's management team will participate in a fireside chat and one-on-one meetings at BTIG's Annual Virtual Biote...
Neutral
GlobeNewsWire
about one month ago
BETHESDA, Md., July 16, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, today announced the pricing of an underwritten public offering of 4,501,640 shares of its common stock and warrants to purchase up to an aggr...
More Gain Therapeutics Inc News

Company Profile

Gain Therapeutics, Inc. is a redefining drug discovery company, which identifies and optimizes allosteric binding sites that never before targeted. Its See-Tx target identification platform uses the published 3D structure of enzymes and a proprietary computational technology to discover new allosteric binding sites and predict their druggability. The firm is also unlocking new treatment options to treat disorders characterized by protein misfolding. The company was founded by Khalid Islam in 2017 and is headquartered in Bethesda, MD.

Head office United States
CEO Gene Mack
Employees 24
Founded 2017
Website www.gaintherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today